<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effectiveness of <z:chebi fb="0" ids="9321">sulbactam</z:chebi>/cefoperazone (SBT/<z:chebi fb="0" ids="3647">CPZ</z:chebi>) on severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> associated with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> was evaluated in a nation-wide multicenter clinical study </plain></SENT>
<SENT sid="1" pm="."><plain>SBT/<z:chebi fb="0" ids="3647">CPZ</z:chebi> (4-6 g/day), a 1:1 combination of SBT and <z:chebi fb="0" ids="3647">CPZ</z:chebi>, was given intravenously to 437 patients with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The underlying diseases included <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and others </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, 94.3% of the patients had <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The complicating <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> included <z:hpo ids='HP_0100806'>sepsis</z:hpo> in 41 cases; <z:hpo ids='HP_0100806'>sepsis</z:hpo> suspected in 205; <z:hpo ids='HP_0002090'>pneumonia</z:hpo> in 47; <z:hpo ids='HP_0000010'>urinary tract infection</z:hpo> in 15; <z:hpo ids='HP_0001945'>fever</z:hpo> of unknown origin in 59; and others in 70 </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical efficacies of SBT/<z:chebi fb="0" ids="3647">CPZ</z:chebi> were as follows; markedly effective, 83 cases; effective, 170; fairly effective, 59; and ineffective, 110 </plain></SENT>
<SENT sid="6" pm="."><plain>The efficacy rate (markedly effective plus effective) was 60.0% as a whole </plain></SENT>
<SENT sid="7" pm="."><plain>The efficacy rate of SBT/<z:chebi fb="0" ids="3647">CPZ</z:chebi> in <z:hpo ids='HP_0100806'>sepsis</z:hpo> and suspected cases, which accounted for 56.3% of the <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, was 59% </plain></SENT>
<SENT sid="8" pm="."><plain>Mild side effects such as <z:hpo ids='HP_0000988'>skin rash</z:hpo> were observed in 15 patients (3.1%) </plain></SENT>
<SENT sid="9" pm="."><plain>As for abnormal laboratory test results, transient increases in GOT, GPT, A1-P, LDH, etc. were observed in 42 patients (8.6%) </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, SBT/<z:chebi fb="0" ids="3647">CPZ</z:chebi> is considered to be a useful drug in empiric therapy for severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> associated with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
</text></document>